Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News ALT5 Sigma Corp ALTS

ALT5 Sigma Corporation, formerly JanOne Inc., is a multidisciplinary organization with a focus on healthcare and fintech. Through its fintech activities, it provides blockchain-powered technologies to enable a migration to a new global financial paradigm for the trading, clearing, settlement, payment, and custodianship of digital instruments. Through its fintech subsidiaries, it offers two main... see more

Recent & Breaking News (NDAQ:ALTS)

JanOne Inc. added to the Russell Microcap® Index

PR Newswire June 3, 2024

ALT 5 Sigma, a wholly-owned subsidiary of JanOne to Present at the iFX Expo, the World's largest online trading conference and tradeshow

PR Newswire May 28, 2024

JanOne Closes Acquisition of ALT 5 Sigma Inc., a Leading Next Generation Blockchain Fintech

PR Newswire May 16, 2024

JanOne to Acquire ALT 5 Sigma Inc., a Leading Next Generation Blockchain Financial Technology Provider

PR Newswire May 13, 2024

JanOne to Acquire ALT 5 Sigma Inc., a Leading Next Generation Blockchain Financial Technology Provider

PR Newswire May 10, 2024

JanOne Regains Compliance with Nasdaq's Listing Requirements

PR Newswire March 15, 2024

JanOne to Present at the Dawson James 8th Annual Investment Conference

PR Newswire September 21, 2023

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

PR Newswire August 31, 2023

JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

PR Newswire August 29, 2023

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

PR Newswire August 25, 2023

JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire August 22, 2023

JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules

PR Newswire August 18, 2023

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

PR Newswire August 18, 2023

JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

PR Newswire June 28, 2023

JanOne Completes Pre-IND Meeting with FDA on Jan123

PR Newswire April 18, 2023

JanOne to Present Data On Its Two Non-Opioid Drug Candidates at The Appalachian Region Spine and Pain Meeting on Drug Development Programs to Treat Pain on April 15, 2023

PR Newswire April 13, 2023

JanOne Technologies Announces Closing of Registered Direct Offering of Common Stock Priced At-The-Market

PR Newswire March 24, 2023

JanOne Welcomes John Bonfiglio -- Veteran Biotech Executive, Deal Maker and Strategist -- to Top Management Team

PR Newswire March 23, 2023

JanOne Technologies Announces Registered Direct Offering of Common Stock Priced At-The-Market

PR Newswire March 23, 2023

JanOne Sells Legacy Business ARCA Recycling to Concentrate on Growing BioPharm Businesses

PR Newswire March 22, 2023